GemPharmatech - Public Comps and Valuation Multiples

GemPharmatech Overview

About GemPharmatech

GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.

Founded

2017

HQ

Employees

1.6K+

Website

gempharmatech.us

Sectors

Drug Development & Therapeutics
Laboratory Services
BioTech

Financials

LTM Revenue $110M

LTM EBITDA $30.6M

EV

$803M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

GemPharmatech Financials

As of November 2025, GemPharmatech reported last 12-month revenue of $110M and EBITDA of $30.6M.

In the same period, GemPharmatech generated $69.4M in LTM gross profit and $18.3M in net income.

See GemPharmatech valuation multiples based on analyst estimates

GemPharmatech P&L

In the most recent fiscal year, GemPharmatech reported revenue of $97.1M and EBITDA of $29.4M.

GemPharmatech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See GemPharmatech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$110M	XXX	$97.1M	XXX	XXX	XXX
Gross Profit	$69.4M	XXX	$60.2M	XXX	XXX	XXX
Gross Margin	63%	XXX	62%	XXX	XXX	XXX
EBITDA	$30.6M	XXX	$29.4M	XXX	XXX	XXX
EBITDA Margin	28%	XXX	30%	XXX	XXX	XXX
EBIT	$20.0M	XXX	$17.3M	XXX	XXX	XXX
EBIT Margin	18%	XXX	18%	XXX	XXX	XXX
Net Profit	$18.3M	XXX	$15.5M	XXX	XXX	XXX
Net Margin	17%	XXX	16%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for GemPharmatech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $110M. EBITDA for the last twelve months was $30.6M. In the most recent fiscal year, GemPharmatech achieved $97.1M in revenue and $29.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$110M	Analyst estimates available to subscribers	$97.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$69.4M	Analyst estimates available to subscribers	$60.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	62.9% gross margin	Analyst estimates available to subscribers	62.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$30.6M	Analyst estimates available to subscribers	$29.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	27.7% EBITDA margin	Analyst estimates available to subscribers	30.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$20.0M	Analyst estimates available to subscribers	$17.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	18.1% EBIT margin	Analyst estimates available to subscribers	17.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$18.3M	Analyst estimates available to subscribers	$15.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	16.6% net profit margin	Analyst estimates available to subscribers	16.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for GemPharmatech

This financial data table provides comprehensive performance metrics for GemPharmatech, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

GemPharmatech generated $110M in revenue over the last twelve months.
The company achieved $30.6M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $69.4M.
Net income over the last twelve months reached $18.3M.

Fiscal Year Performance

In the most recent fiscal year, GemPharmatech reported $97.1M in total revenue.
Fiscal year EBITDA was $29.4M.
The company maintained a gross profit margin of 62.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 30.3%.
Net profit margin reached 16.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for GemPharmatech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

GemPharmatech Stock Performance

GemPharmatech has current market cap of CNY 6.6B (or $926M), and EV of CNY 5.7B (or $803M).

Market Cap Evolution

GemPharmatech Stock Data

As of December 3, 2025, GemPharmatech's stock price is CNY 16 (or $2).

See GemPharmatech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$803M	$926M	XXX	XXX	XXX	XXX	$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

GemPharmatech Valuation Multiples

GemPharmatech's trades at 8.3x EV/Revenue multiple, and 27.3x EV/EBITDA.

See valuation multiples for GemPharmatech and 15K+ public comps

GemPharmatech Financial Valuation Multiples

As of December 3, 2025, GemPharmatech has market cap of $926M and EV of $803M.

Equity research analysts estimate GemPharmatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

GemPharmatech has a P/E ratio of 50.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$926M	XXX	$926M	XXX	XXX	XXX
EV (current)	$803M	XXX	$803M	XXX	XXX	XXX
EV/Revenue	7.3x	XXX	8.3x	XXX	XXX	XXX
EV/EBITDA	26.3x	XXX	27.3x	XXX	XXX	XXX
EV/EBIT	40.1x	XXX	46.4x	XXX	XXX	XXX
EV/Gross Profit	11.6x	XXX	n/a	XXX	XXX	XXX
P/E	50.7x	XXX	59.7x	XXX	XXX	XXX
EV/FCF	36.1x	XXX	-243.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get GemPharmatech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

GemPharmatech Margins & Growth Rates

GemPharmatech's last 12 month revenue growth is 16%

GemPharmatech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $27K for the same period.

GemPharmatech's rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GemPharmatech's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for GemPharmatech and other 15K+ public comps

GemPharmatech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	16%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	28%	XXX	30%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	0%	XXX	XXX	XXX
Rule of 40	51%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	69%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$27K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	44%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial